Rheumatology 

John Sealy

ResearchRheumatology


  • Antiphospholipid Antibodies and Lupus: New Molecular Targets for Treatment, NIH-sponsored, 2013 - present
  • A Multicenter International Prospective, Randomized Controlled Trial of Hydroxychloroquine in the Primary Thrombosis Prophylaxis of Persistently Antiphospholipid Antibody (aPL) Positive but Thombosis-free Patients without Systemic Autoimmune Disease, 2013 - present
  • An Open-Label Proof of Concept Phase IIa Trial of ALXN1007 for the Treatment of Non-criteria Manifestations of Antiphospholipid Syndrome, 2013 - present
  • A Phase IIb, Multi-Center, Randomized, Double-Blind,Placebo-Controlled, Multidose, 24-Week Study to Evaluate the Efficacy and Safety of Atacicept (TACI-Ig) in Subjects With Systemic Lupus Erythematosus (SLE), 2014 - present.
  • "Treat-to-Target", a multi-center trial of RA, NIH-sponsored, out of Harvard university, Boston, under the leadership of Dr. Daniel Salomon, 2014 - present
  • Determination of cultured endothelial cells to examine the effects of various inhibitors that may block their binding and activation determine their thrombogenic effects in mice, 2007 - present
  • Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) International Clinical Database and Repository Collaborative Registry, 2013 - present

Staff

  • Zurina Romay-Penabad

    Romay-Penabad, Zurina
    Research Associate II

    Division: Rheumatology
    Department: Internal Medicine

    Email: zuromayp@utmb.edu 
  • Schleh, Alvaro

    Schleh, Alvaro
    Coordinator I

    Division: Rheumatology
    Department: Internal Medicine

    Emailalschleh@utmb.edu
  • Willis, Rohan

    Willis, Rohan
    Research Scientist I

    Division: Rheumatology
    Department: Internal Medicine

    Emailrowillis@utmb.edu